AdAlta

Home

AdAlta CEO and Managing Director, Tim Oldham, sits down with Sharewise's Caitlyn Cheung to present on the following themes:

The diseases AdAlta's i-body ® drug candidates are targeting

AD-214, AdAlta’s initial drug candidate, which is now on the cusp of Phase 2 clinical trials

AdCella, AdAlta’s new “east to west” cellular immunotherapy strategy

AdAlta's strategic partnerships and how they are accelerating drug development

Key target development milestones for the coming year

This presentation was followed by questions from the audience.